Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infographic: Cancer Deal-Making In 2020

Executive Summary

Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 23 with upfront value of at least $100m.

2020 has been a hectic deal-making year for the biopharmaceutical industry, with the most significant deals – Gilead Sciences, Inc./Immunomedics, Inc. and Merck & Co., Inc./Seattle Genetics, Inc. – occurring in recent days, despite the ongoing COVID-19 pandemic. Deal-making in cancer has been particularly voluminous, continuing the trend of recent years. In this infographic, we mine information from Scrip coverage from  the and the Biomedtracker database to provide a snapshot of the year’s cancer deal-making as of mid-September – highlighting the most significant acquisitions and alliances, gathering in one place the highest-value transactions, and also depicting which companies were most active and what development stages and therapeutic modalities saw the greatest activity.






To download this infographic, click here.

Related Content


Key Documents

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts